[HTML][HTML] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic …
RT Swords, J Watts, HP Erba, JK Altman, M Maris… - Blood cancer …, 2017 - nature.com
Dear Sir, We previously reported the therapeutic potential of pevonedistat (TAK-
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
[PDF][PDF] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic …
CRL NEDD - Blood Cancer Journal, 2017 - dukespace.lib.duke.edu
Dear Sir, We previously reported the therapeutic potential of pevonedistat (TAK-
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
RT Swords, J Watts, HP Erba, JK Altman… - Blood Cancer …, 2017 - europepmc.org
Dear Sir, We previously reported the therapeutic potential of pevonedistat (TAK-
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
RT Swords, J Watts, HP Erba, JK Altman… - Blood Cancer …, 2017 - search.proquest.com
Dear Sir, We previously reported the therapeutic potential of pevonedistat (TAK-
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
[引用][C] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic …
RT Swords, J Watts, HP Erba, JK Altman… - Blood cancer …, 2017 - ohsu.elsevierpure.com
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor,
in patients with acute myeloid leukemia and myelodysplastic syndromes — Oregon Health & …
in patients with acute myeloid leukemia and myelodysplastic syndromes — Oregon Health & …
[引用][C] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic …
RT Swords, J Watts, HP Erba… - … cancer journal (New …, 2017 - scholarship.miami.edu
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes
RT Swords, J Watts, HP Erba, JK Altman… - Blood cancer …, 2017 - pubmed.ncbi.nlm.nih.gov
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in
patients with acute myeloid leukemia and myelodysplastic syndromes Expanded safety …
patients with acute myeloid leukemia and myelodysplastic syndromes Expanded safety …
[引用][C] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic …
RT Swords, J Watts, HP Erba… - Blood cancer …, 2017 - scholars.northwestern.edu
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor,
in patients with acute myeloid leukemia and myelodysplastic syndromes — Northwestern …
in patients with acute myeloid leukemia and myelodysplastic syndromes — Northwestern …
[HTML][HTML] Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic …
RT Swords, J Watts, HP Erba, JK Altman… - Blood Cancer …, 2017 - ncbi.nlm.nih.gov
Dear Sir, We previously reported the therapeutic potential of pevonedistat (TAK-
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
924/MLN4924), a novel inhibitor of protein neddylation, in patients with acute myeloid …
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, in patients with acute myeloid leukemia and myelodysplastic syndromes.
RT Swords, J Watts, HP Erba, JK Altman… - Blood Cancer …, 2017 - europepmc.org
Expanded safety analysis of pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor,
in patients with acute myeloid leukemia and myelodysplastic syndromes. - Abstract - Europe …
in patients with acute myeloid leukemia and myelodysplastic syndromes. - Abstract - Europe …